Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy
Division of Clinical and Epidemiological Research, Department of Obstetrics & Gynecology, Duke University Medical Center, Durham, NC, USA. American journal of obstetrics and gynecology
(Impact Factor: 4.7).
06/2011; 204(6 Suppl 1):S128-40. DOI: 10.1016/j.ajog.2011.04.009
The purpose of this review was to estimate the impact of timing of seasonal influenza vaccination during pregnancy on health and economic outcomes. Cost-effectiveness analysis with a dynamic model of the US population of pregnant women and infants who were <6 months incorporated seasonal variation in influenza incidence. Compared with no vaccination, seasonal influenza vaccination in pregnancy costs $70,089 per quality-adjusted life year. Most of the benefit for infants was limited to those whose mothers were vaccinated within the first 4 weeks of vaccine availability. Once all women who were pregnant at the time of vaccine availability were vaccinated, vaccination of newly pregnant women had benefits for mothers but not infants. Delay of vaccination beyond November reduced both effectiveness and cost-effectiveness. The greatest population benefit from seasonal influenza vaccination in pregnancy was realized if pregnant women were vaccinated as soon as possible after trivalent inactivated influenza vaccine became available. Efforts to increase vaccine rates should be concentrated early in the influenza season.
Available from: Ioanna Skountzou
- "During a typical season, the CDC estimates that more than 200,000 hospitalizations, and 40,000 deaths are associated with influenza infection and related complications1, with up to 1.5 million deaths worldwide2. Seasonal influenza infection affects all age groups with the greatest disease severity occurring in the elderly345, persons with underlying chronic diseases67, infants and young children who have not been previously exposed to the virus8, pregnant women910, and health care workers11. "
[Show abstract] [Hide abstract]
ABSTRACT: Influenza infection represents a major socio-economic burden worldwide. Novel delivery methods can render influenza vaccination easier and more acceptable by the public, and importantly confer protection equal or superior to that induced by conventional systemic administration. An attractive target for vaccine delivery is the skin. Recent studies have demonstrated improved immune responses after transdermal delivery of inactivated influenza virus with microneedle patches. Here we show that immunization with a licensed influenza subunit vaccine coated on metal microneedles can activate both humoral and cellular arms of the immune response and confer improved long-term protection in the mouse model when compared to the conventional systemic route of delivery. These results demonstrate the promising potential of microneedle delivery of licensed influenza subunit vaccines, that could be beneficial in increasing vaccine coverage and protection and reducing influenza-related mortality worldwide.
Scientific Reports 04/2012; 2:357. DOI:10.1038/srep00357 · 5.58 Impact Factor
American journal of obstetrics and gynecology 06/2011; 204(6 Suppl 1):S1-3. DOI:10.1016/j.ajog.2011.04.010 · 4.70 Impact Factor
Journal of the American Pharmacists Association 09/2011; 51(5):665-7. DOI:10.1331/JAPhA.2011.11539 · 1.24 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.